Funding Opportunities
Current Funding Opportunities
Title | NIH Guide | RFA Number | Common Fund Contact | Application Receipt Date |
---|---|---|---|---|
Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed) | 4/11/2022 | RFA-RM-22-017 | Marrah Lachowicz-Scroggins marrah.lachowicz-scroggins@nih.gov 301-827-8229 |
Letter of Intent: 6/17/2022 Application Receipt Date: July 19, 2022 |
Platform Clinical Trials of Somatic Genome Editing for Multiple Diseases (UG3/UH3, Clinical Trial Required) | 4/11/2022 | RFA-RM-22-016 | P.J. Brooks pj.brooks@mail.nih.gov 301-443-0513 |
Letter of Intent: 6/17/2022 Application Receipt Date: July 19, 2022 |
IND-enabling Studies of Somatic Genome Editing Therapeutic Leads (U19, Clinical Trial Not allowed)
|
4/11/2022 | RFA-RM-22-015 | Chris Boshoff chris.boshoff@nih.gov 301-496-1779 |
Letter of Intent: 6/17/2022 Application Receipt Date: July 19, 2022 |
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed) |
4/11/2022 | RFA-RM-22-014 | Betty Poon poonb@mail.nih.gov 240-669-5024 |
Letter of Intent: 6/17/2022 Application Receipt Date: July 19, 2022 |
Archived Funding Opportunities
- Notice of Pre-Application Webinar for the NIH Common Fund Somatic Cell Genome Editing program
NOT-RM-18-020 - Development of Cell and Tissue Platforms to Detect Adverse Biological Consequences of Somatic Cell Genome Editing (U01 Clinical Trial Not Allowed)
RFA-RM-18-022 - Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (UG3/UH3 Clinical Trial Not Allowed)
RFA-RM-18-023 - Expanding the Human Genome Engineering Repertoire (U01 Clinical Trial Not Allowed)
RFA-RM-18-024 - Innovative Technologies to Non-Invasively Monitor Genome Edited Cells In Vivo (UH2/UH3 Clinical Trial Not Allowed)
RFA-RM-18-025 - Large Animal Testing Centers for Evaluation of Somatic Cell Genome Editing Tools (U42 - Clinical Trial Not Allowed)
RFA-RM-18-014 - Rodent Testing Centers for Development of Reporter Systems and Evaluation of Somatic Cell Genome Editing Tools (U42 Clinical Trial Not Allowed)
RFA-RM-18-012 - Development of Large Animal Reporter Systems for Testing Somatic Cell Genome Editing Tools (U24 Clinical Trial Not Allowed)
RFA-RM-18-013 - Development of Cell and Tissue Platforms to Detect Adverse Biological Consequences of Somatic Cell Gene Editing (U01 Clinical Trial Not Allowed)
RFA-RM-18-015 - Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (UG3/UH3 Clinical Trial Not Allowed)
RFA-RM-18-016 - Expanding the Human Genome Editing Repertoire (U01 Clinical Trial Not Allowed)
RFA-RM-18-017 - Somatic Cell Genome Editing Dissemination and Coordinating Center (U24 Clinical Trial Not Allowed)
RFA-RM-18-018
This page last reviewed on April 12, 2022